Navigation Links
Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform

CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT™ fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be used in the development of its bi-specific antibody platform targeting three therapeutic areas: Oncology, Immuno-Oncology and Immunology.

Under the agreement, Oncobiologics will gain access to XOMA's highly diverse library of scFv antibodies and associated patent estate, and will utilize XOMA's know-how and proven software tools as it advances its own candidates for treating cancer and immune diseases. Financial terms were not disclosed.

Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics, commented, "We are very excited to partner with XOMA to advance our discovery pipeline. Their proven technology represents an important asset to support our strategy to deliver improved efficacy and safety in our drug candidates. Access to this technology is a key differentiator for the bi-specific mAb candidates in our pipeline and we believe this creates significant value for our programs."

Joseph Bertino, M.D., Chief Scientific Officer of the Cancer Institute of New Jersey and Head of Oncobiologics' Scientific Advisory Board, added, "Fully human single chain antibodies in a bi-specific format offer promising opportunities for a new class of biotherapeutics designed to enhance efficacy and safety. Bringing together these capabilities with Oncobiologics' platform creates an exciting pathway for enhancing oncology treatment."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TriDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery.  For more information, please visit or call 609-619-3990.


Stephen J. McAndrew, Ph.D.
Oncobiologics, Inc.
609-619-3990, ext. 216

Rick Gregory

This press release was issued through eReleases® Press Release Distribution. For more information, visit  

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Record Second Quarter Results
2. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
3. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
4. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
5. IDEXX Laboratories Announces Second Quarter Results
6. Amgen Announces 2012 Third Quarter Dividend
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. Critical Process Filtration Announces New Website and Expanded Literature Library
9. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
10. Neogen Corporation Announces Year-End Results Conference Call
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):